

## **Oncopeptides to host a Capital Markets Day in New York on December 14<sup>th</sup>**

**Stockholm – October 25, 2018 - Oncopeptides AB (Nasdaq Stockholm: ONCO) announced today that they will host a Capital Markets Day on December 14<sup>th</sup> between 8.30-11.00 AM ET in New York. Speakers will include Jakob Lindberg, Chief Executive Officer, other members of management and Professor Paul G Richardson, Dana-Farber Cancer Institute, Clinical Program Leader & Director of Clinical Research, Jerome Lipper Multiple Myeloma Center. The event will also be webcasted. A detailed program will be published in beginning of December.**

**For further information, please contact:**

Rein Piir, Head of Investor Relations at Oncopeptides AB

E-mail: rein.piir@oncopeptides.com

**RSVP to Alan Lada at [alada@troutgroup.com](mailto:alada@troutgroup.com)**

This information was submitted for publication at 10.30 CET October 25, 2018

### **About Oncopeptides**

Oncopeptides is a pharmaceutical company developing drugs for the treatment of cancer. The company is focusing on the development of the lead product candidate Ygalo®, an alkylating peptide, belonging to a new class of drugs (Peptidase Enhanced Compounds - PEnCs). Ygalo® is intended as an effective treatment of hematological cancers, and in particular multiple myeloma. The goal with the current clinical study program is to demonstrate better results from treatment with Ygalo® compared with established alternative drugs for patients with late-stage multiple myeloma. Ygalo® will potentially provide physicians with a new treatment option for patients suffering from this serious disease.

**Visit [www.oncopeptides.se](http://www.oncopeptides.se) for more information.**